Sickle Cell Gene Therapy Potency Assay Using Hypoxic Cell Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an objective and robust assay to quantify the potency of gene therapy treatments for sickle cell disease, particularly in assessing the morphological changes in red blood cells induced by low oxygen conditions.
Innovation Solution
A potency assay involving transduction of hematopoietic stem or progenitor cells with a lentiviral vector encoding a globin, followed by two-phase erythroid differentiation under hypoxia, fixation, staining, and analysis using an imaging device to calculate the Sickle Index, which quantifies the proportion of sickled cells relative to untransduced controls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional subjective assessment methods are used to evaluate gene therapy potency, then the assessment process is simpler, but the measurement precision and reliability are insufficient
Solution Approach 1:
The patent replaces manual, subjective assessment methods with an automated imaging-based system. The imaging device captures morphological changes of red blood cells, and image analysis algorithms automatically calculate the Sickle Index, eliminating human subjectivity and improving measurement precision while maintaining manageable system complexity through software automation.
Solution Approach 2:
The patent utilizes the morphological color and shape changes of red blood cells under hypoxia conditions as the basis for potency assessment. By imaging the visual appearance and calculating the Sickle Index from these visual changes, the system achieves objective, quantitative measurement of gene therapy effectiveness without requiring complex biochemical assays.
2Reliability
If subjective assessment methods are used, then the assay procedure is simpler, but the reliability and objectivity of potency evaluation deteriorates
Solution Approach 1:
The patent replaces subjective human assessment with an automated imaging and image analysis system. The imaging device objectively captures cell morphology, and computational algorithms automatically calculate the Sickle Index, ensuring consistent and reliable results across different operators and time points while managing system complexity through software automation.
Solution Approach 2:
The patent establishes a feedback loop where the imaging system continuously monitors and quantifies morphological changes, and the calculated Sickle Index provides quantitative feedback on gene therapy potency. This objective feedback mechanism improves assay reliability by eliminating operator bias and enabling consistent evaluation criteria.
3Measurement precision
If conventional potency assays are used, then the assay development time is shorter, but the ability to objectively quantify morphological changes under hypoxia is insufficient
Solution Approach 1:
The patent replaces conventional biochemical or subjective morphological assessment methods with automated imaging technology. The imaging device directly captures and quantifies morphological changes of red blood cells under hypoxia, providing precise measurement of sickling phenotype without requiring complex sample preparation or lengthy analysis protocols, thus achieving accurate quantification with reasonable implementation time.
4Measurement precision
If the assay uses complex multi-parameter analysis, then the measurement precision improves, but the ease of operation decreases
Solution Approach 1:
The patent merges multiple assessment parameters into a single composite metric called the Sickle Index. By combining morphological features from imaging data into one quantitative value, the system maintains high measurement precision for potency assessment while simplifying the operational workflow and data interpretation for users.
Solution Approach 2:
The imaging-based assay system serves multiple functions: it captures cell morphology, quantifies morphological changes, calculates the Sickle Index, and evaluates gene therapy potency all within a single integrated platform. This multi-functionality maintains measurement precision while improving ease of operation by eliminating the need for multiple separate assays.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a reliable and precise method to assess the efficacy of gene therapy treatments by measuring the reduction in sickled cells, correlating with vector copy number and protein expression, suitable for in vitro characterization of anti-sickling properties.
Implementation Method 1
Under low oxygen conditions, HbS polymerizes and causes red blood cells (RBCs) to morphologically change to the characteristic 'sickled' shape
Implementation Method 2
analyzing the fixed and stained erythroid cells with an imaging device
Data Source
AI summary
Disclosed herein are potency assays for a gene therapy treatment for sickle cell disease. Also disclosed herein are methods for measuring relative potency of a drug product used for the treatment of sickle cell disease.